Akouos, Inc.
Clinical trials sponsored by Akouos, Inc., explained in plain language.
Develops gene therapies for hearing loss and inner ear disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
One-shot gene therapy aims to shrink ear tumors without surgery
Disease control Recruiting nowThis early-stage trial tests a gene therapy given as a single injection into the inner ear for people with a non-cancerous tumor called vestibular schwannoma. The therapy uses a harmless virus to deliver a gene that blocks blood vessel growth to the tumor, potentially stopping it…
Phase 1/2 • Sponsor: Akouos, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Gene therapy aims to restore hearing in children with rare genetic deafness
Disease control Recruiting nowThis trial tests a gene therapy called AAVAnc80-hOTOF for people with severe hearing loss caused by mutations in the otoferlin gene. The therapy is given as a single injection into the inner ear during surgery. The study will check if the treatment is safe and if it can improve h…
Phase 1/2 • Sponsor: Akouos, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Scientists track rare genetic hearing loss over time
Knowledge-focused Recruiting nowThis study follows up to 150 people with hearing loss caused by changes in the otoferlin gene. Researchers will measure hearing function using tests like auditory brainstem response (ABR) and otoacoustic emissions (OAE). The goal is to learn how this type of hearing loss changes …
Sponsor: Akouos, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC